The μ-opioid receptor, or MOR, is the primary molecular target for most clinically used analgesic opioids, from morphine to fentanyl. Decades of research have focused on what happens at the plasma membrane, where activated receptors are phosphorylated, bind β-arrestin, and are pulled into the cell by endocytosis. Chronic exposure to certain agonists reduces the number of receptors displayed on the cell surface, a process widely believed to contribute to tolerance and dependence. But the new work shifts attention to a much earlier stage of the receptor’s life: its maturation and export from the endoplasmic reticulum, the cellular factory where membrane proteins are synthesized and folded.

Studying this early phase in normal receptors is difficult because MORs traffic efficiently to the plasma membrane, leaving almost nothing in the endoplasmic reticulum to observe. To overcome this obstacle, the research team, led by Matthew J. Mulcahy, Stephen N. Grant, and Henry A. Lester, used a rare mutant called MOR[N190K], which is substantially retained in the endoplasmic reticulum. When cells expressing this mutant were treated with the antagonists naltrexone or naloxone, fluorescently tagged receptors suddenly appeared outlining the cell surface, reaching a distribution resembling that of the wild-type receptor. The drugs, in other words, had rescued the mutant receptor’s journey to the membrane.

The mechanism behind this rescue appears to involve endoplasmic reticulum exit sites, or ERES, specialized regions of the organelle where newly folded cargo is packaged into coat protein vesicles for transport to the Golgi apparatus. To visualize these structures, the researchers used a fluorescently tagged version of Sec24D, a core component of the ERES machinery. First, they needed to confirm that the receptor and Sec24D actually interact. Using sensitized emission Förster resonance energy transfer, a live-cell technique that detects when two fluorescently labeled proteins come within a few nanometers of each other, they showed that MOR[N190K] sits in close proximity to Sec24D inside the endoplasmic reticulum. A control experiment with Rab5, a marker of early endosomes, produced no comparable signal, ruling out the possibility that the interaction was happening after the receptor had already reached the cell surface and been internalized.

With that interaction established, the team turned to three-dimensional confocal microscopy to ask what happens to ERES when cells are flooded with opioid drugs. They measured the fraction of the cytoplasmic volume occupied by ERES, a metric chosen because, as earlier work by Heinzer and colleagues reasoned, expanding the size of exit sites is a more effective way to boost secretory flux than simply adding more of them. After twelve hours of treatment with ten micromolar concentrations of drug, four ligands stood out: naltrexone, naloxone, morphine, and fentanyl all significantly increased the ERES fraction. Buprenorphine, methadone, and two positive allosteric modulators, BMS 986122 and BMS 986124, did not.

The pattern held up under several additional tests. N-methyl-naltrexone, a permanently charged derivative of naltrexone that crosses the plasma membrane far less readily, produced only a modest shift in ERES levels, consistent with the idea that the drug must physically enter the cell and reach the endoplasmic reticulum to chaperone the receptor. A shorter four-hour incubation with naltrexone yielded only a partial increase, suggesting that the process builds over time as receptors cycle through the secretory pathway. And when the researchers blocked COPI-dependent retrograde transport with brefeldin A, naltrexone and naloxone lost their ability to raise ERES levels entirely. That last result implies that the mutant receptor must make multiple round trips between the endoplasmic reticulum and the Golgi before it is fully matured and ready for the plasma membrane, a requirement that mirrors findings from pharmacological chaperoning studies of other receptor families.

Perhaps the most intriguing result came from a double mutant. Serine 375, a residue in the receptor’s C-terminal tail, is a well-known phosphorylation site that governs arrestin recruitment and receptor internalization at the cell surface. When the researchers mutated this serine to alanine in the ER-retained background, creating MOR[N190K][S375A], naltrexone still chaperoned the receptor effectively, but morphine and fentanyl lost their chaperoning power altogether. This suggests that the agonists’ ability to promote receptor export depends on S375, possibly because they can induce phosphorylation of the residue even while the receptor is still maturing inside the endoplasmic reticulum. It also reveals an unexpected, “inside-out” role for a residue that has almost exclusively been studied in the context of events at the plasma membrane.

The team also tested and rejected an alternative explanation for the upregulation. One hypothesis held that antagonists raise intracellular cyclic AMP levels, which in other cell types has been shown to coincide with a global increase in protein trafficking. Because MOR activation suppresses cAMP, blocking basal receptor activity with an antagonist could plausibly raise cAMP and thereby accelerate trafficking generally. But a competitive ELISA assay on cell lysates showed no significant cAMP increase after twelve hours of naltrexone treatment, while the positive control, forskolin, produced the expected rise. With the cAMP pathway ruled out, the pharmacological chaperoning hypothesis stands as the leading explanation for how these ligands expand ERES levels and push the mutant receptor toward the cell surface.

The clinical stakes of this basic cell biology are considerable. Naltrexone and naloxone are the two most commonly prescribed opioid antagonists, given to people recovering from opioid use disorder. Chronic antagonist treatment is known to increase the number of opioid receptors on the cell surface, producing a supersensitivity that can persist for weeks after the final dose. If a patient relapses during that window, the expanded receptor population raises the risk of a fatal overdose. Understanding that antagonists may drive this upregulation, at least in part, by chaperoning receptors through the early secretory pathway opens a potential strategy for decoupling the therapeutic benefits of antagonist therapy from its most dangerous side effect.

The authors are careful about the limits of their findings. In pilot experiments, neither naltrexone nor the other ligands increased ERES levels or surface expression of the wild-type receptor, so the chaperoning mechanism demonstrated here applies only to the rare MOR[N190K] mutant, and the microscopy approach cannot yet be applied to native neurons in intact neural circuits. Generalizing the mechanism to explain supersensitivity in animals with normal receptors will require additional, still unknown elements of the chaperoning process, much as the mechanisms behind nicotine’s selective upregulation of nicotinic receptors in certain cell types remain only partly resolved. Interestingly, buprenorphine’s known ability to rescue the mutant receptor’s surface expression despite failing to raise ERES levels suggests that it acts through a different, ERES-independent trafficking step, hinting that multiple routes to the plasma membrane can be targeted by small molecules.

Even with those caveats, the study makes a strong case that pharmacological chaperoning deserves a place in any complete account of a drug’s efficacy profile. Ligands long classified purely by their actions at the cell surface, agonists and antagonists alike, turn out to influence the internal processing of their own receptors, changing how cells respond to drug exposure from the inside out. As the authors note, this principle now appears to span several drugs of abuse, from nicotine to opioids, and the hope is that future experiments will keep following opioid receptors into the endoplasmic reticulum and Golgi, far from the plasma membrane where most of their story has been told until now.

Subject of Research: Pharmacological chaperoning of the μ-opioid receptor by opioid agonists and antagonists via endoplasmic reticulum exit sites

Article Title: Naltrexone, Naloxone, Morphine, and Fentanyl Pharmacologically Chaperone a Mutant μ‐Opioid Receptor via an Endoplasmic Reticulum Exit Site‐Dependent Pathway

Article References: Grant, S. N., Mulcahy, M. J., & Lester, H. A. (2026). Naltrexone, Naloxone, Morphine, and Fentanyl Pharmacologically Chaperone a Mutant μ‐Opioid Receptor via an Endoplasmic Reticulum Exit Site‐Dependent Pathway. Pharmacology Research & Perspectives, 14(5), Article e70315. https://doi.org/10.1002/prp2.70315

Image Credits: AI Generated

DOI: 10.1002/prp2.70315

Keywords: μ-opioid receptor, pharmacological chaperoning, naltrexone, naloxone, fentanyl, morphine, endoplasmic reticulum exit sites, Sec24D, opioid use disorder, receptor trafficking, S375 phosphorylation, inside-out pharmacology

The flexibility and dynamic nature of ERES are crucial in how they adapt to varying cellular states and environmental conditions. This adaptability is particularly evident as ERES integrate a multitude of signals from their cellular environment – including cargo load, membrane tension, and spatial information – to dynamically alter their architecture and functionality in real time. The ongoing research indicates that this ability for ERES to change their structure and operational mode not only supports their traditional role in protein export but also resonates with their involvement in diverse cellular processes.

One of the key aspects of ERES functionality lies in their biogenesis. These structures do not arise randomly; rather, specific molecular and cellular cues drive their formation and maturation. Dissecting the molecular machinery that governs ERES biogenesis has become a focal point for researchers. The proteins and lipids involved in constructing ERES are now at the center of investigation, as an understanding of these determinants promises to illuminate how cells orchestrate intricate trafficking networks through well-defined portals.

As our grasp of the structural diversity of ERES advances, the complexity of these exit sites becomes increasingly evident. They exhibit considerable variation not only between different cell types but also within the same cell under varying physiological conditions. The regulatory mechanisms that lead to these variations are critical to fully understanding ERES, thereby providing insights into how cells adapt to the demands of their microenvironment. This variability in ERES architecture suggests the adaptive nature of cellular compartments, enabling cells to navigate fluctuating metabolic demands.

The coordination of protein trafficking is governed through an interplay of signaling pathways that fine-tune the dynamics between ERES and their cargo. This regulation is particularly significant under stress conditions or during cellular differentiation. Cells often find themselves in environments that necessitate rapid adjustments in their trafficking systems, making the signaling mechanisms surrounding ERES vital. Specialized sensor proteins likely facilitate the communication between the cargo load and ERES, allowing cells to prioritize trafficking under changing conditions.

The intricate balance between the structural integrity of ERES and the efficiency of protein export further highlights the functional plasticity of these sites. Membrane tension, for example, is known to play a crucial role in ERES functioning, with studies suggesting that variations in membrane composition can remodel their architecture. This tension may serve not only as a physical constraint but also as a signaling mechanism that helps maintain robust protein export under varying states of flux.

Emerging concepts in systems biology have stimulated a more holistic approach towards understanding ERES. Research initiatives now aim to integrate high-resolution imaging techniques, such as super-resolution microscopy, synthetic reconstitution approaches, and computational modeling. These interdisciplinary strategies promise to dissect the mechanistic principles governing ERES function and enable researchers to visualize and quantify dynamic changes occurring at these sites. Through this synthesis of methods, novel insights into cellular trafficking phenomena can be achieved, paving the way for an integrated framework that accounts for both the structural and functional dimensions of ERES.

The potential ramifications of this research extend far beyond academic curiosities. Understanding the mechanisms underpinning ERES operation holds immense promise for therapeutic strategies targeting trafficking dysfunction. Several diseases—ranging from neurodegenerative disorders to metabolic syndromes—are linked to disruptions in these cellular transport processes. Targeting ERES function in these contexts could offer novel avenues for intervention, potentially restoring normal trafficking dynamics and alleviating disease symptoms.

Finally, key questions in this research landscape remain unanswered. How do ERES traverse the delicate line between structure and plasticity? What are the precise molecular events that dictate their adaptive responses to cellular states? What role does the microenvironment play in shaping ERES function? The responses to these queries can forge a comprehensive understanding of ERES and, in turn, their contributions to cellular physiology.

The future of ERES research lies not just in uncovering their basic biology but also in elucidating their operational frameworks. The push towards developing a unified theory on ERES function will require rigorous interrogation of existing paradigms and a welcoming of new concepts. It is an exciting time to be involved in this research area as scientists strive to correlate foundational insights into ERES with their implications for health and disease.

As we delve deeper into ERES mechanisms, it is essential to underscore their multifaceted nature. The journey to unravel the mysteries of ERES is akin to opening a Pandora’s box of cellular dynamics. In doing so, we can anticipate breakthroughs that will not only enhance our biological understanding but also translate into practical, therapeutic advancements.

In conclusion, the study of ERES marks a pivotal frontier in molecular and cellular biology. As researchers continue to explore these enigmatic structures, the potential to reshape our approach to health and disease through targeted interventions grows increasingly responsive to their discoveries. ERES stand not just as exit sites for protein traffic but as critical hubs of cellular communication, highlighting the complexity of life at the molecular level.

Subject of Research: Endoplasmic Reticulum Exit Sites (ERES)

Article Title: Towards a unified framework for the function of endoplasmic reticulum exit sites

Article References:

Farhan, H., Raote, I., Campelo, F. et al. Towards a unified framework for the function of endoplasmic reticulum exit sites.
Nat Rev Mol Cell Biol (2025). https://doi.org/10.1038/s41580-025-00899-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41580-025-00899-0

Keywords: Endoplasmic Reticulum, ERES, COPII, Protein Trafficking, Autophagy, Lipid Droplets, Membrane Tension, High-Resolution Imaging, Cellular Dynamics, Disease Mechanisms